Moreover, highly aggressive angiosarcomas exhibit considerable genomic plasticity, allowing them to activate alternative signaling pathways (e.g., MET, AXL, and MAS) (13, 16), thereby bypassing VEGFR inhibition by sunitinib. The gene discussed is MAS1; the disease is angiosarcoma.